Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Neoplasms 4 Thyroid Cancer, Papillary 3 Adenocarcinoma, Follicular 3 Neoplasm Metastasis 1 Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1 Differentiated Thyroid Cancer 1

Interventions

surufatinib 1 pembrolizumab 1 lenvatinib 1 donafenib 1 Thyrotropin Alfa 1 Sorafenib 1 Injections 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Differentiated Thyroid Cancer × Thyrotropin Alfa × Clear all

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡